cefoperazone has been researched along with Community Acquired Infection in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caniça, M; Ferreira, E; Leitão, J; Manageiro, V; Mendonça, N | 1 |
| Chen, CH; Chen, CM; Chen, WC; Fang, WF; Fu, PK; Huang, CT; Ku, SC; Kuo, LK; Lai, CC; Tu, CY; Wang, YT | 1 |
| Fang, X; Huang, F; Wang, J; Yu, J | 1 |
| Chen, CH; Chen, CM; Chen, WC; Cheng, WC; Fang, WF; Fu, PK; Ku, SC; Kuo, LK; Lai, CC; Tu, CY; Wang, YT | 1 |
| Sadikot, RT; Swenson, CE | 1 |
| Liu, H; Liu, J; Xiong, S; Xiong, W; Xu, S; Xu, Y; Zhao, J | 1 |
1 review(s) available for cefoperazone and Community Acquired Infection
| Article | Year |
|---|---|
Achromobacter respiratory infections.
Topics: Achromobacter; Age Factors; Anti-Bacterial Agents; Bronchiectasis; Cefoperazone; Cephalosporins; Community-Acquired Infections; Comorbidity; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Neoplasms; Penicillins; Piperacillin; Pneumonia, Bacterial; Respiratory Tract Infections; Risk Factors; Sex Factors; Ticarcillin; Virulence Factors | 2015 |
1 trial(s) available for cefoperazone and Community Acquired Infection
| Article | Year |
|---|---|
Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefoperazone; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome | 2006 |
4 other study(ies) available for cefoperazone and Community Acquired Infection
| Article | Year |
|---|---|
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Middle Aged; Portugal | 2007 |
Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefoperazone; Cohort Studies; Community-Acquired Infections; Female; Frail Elderly; Healthcare-Associated Pneumonia; Humans; Male; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Retrospective Studies; Sulbactam; Treatment Outcome | 2022 |
Investigation and Analysis of Infection among Inpatients in a Tertiary Hospital in Shanghai.
Topics: Adult; Anti-Bacterial Agents; Cefoperazone; China; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Humans; Inpatients; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Retrospective Studies; Sulbactam; Tertiary Care Centers | 2022 |
The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Cefoperazone; Community-Acquired Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Retrospective Studies; Sulbactam; Treatment Outcome | 2023 |